Retrospective Study
Copyright ©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastroenterol. Sep 14, 2020; 26(34): 5130-5145
Published online Sep 14, 2020. doi: 10.3748/wjg.v26.i34.5130
Golgi protein-73: A biomarker for assessing cirrhosis and prognosis of liver disease patients
Nikolaos K Gatselis, Tamás Tornai, Zakera Shums, Kalliopi Zachou, Asterios Saitis, Stella Gabeta, Roger Albesa, Gary L Norman, Mária Papp, George N Dalekos
Nikolaos K Gatselis, Kalliopi Zachou, Asterios Saitis, Stella Gabeta, George N Dalekos, Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Larissa 41110, Greece
Nikolaos K Gatselis, Kalliopi Zachou, George N Dalekos, Institute of Internal Medicine and Hepatology, Larissa 41447, Greece
Tamás Tornai, Mária Papp, Department of Internal Medicine, Division of Gastroenterology, University of Debrecen, Faculty of Medicine, Debrecen H-4032, Hungary
Zakera Shums, Roger Albesa, Gary L Norman, Department of Research and Development, Inova Diagnostics, Inc., San Diego, CA 92131, United States
Author contributions: Gatselis NK, Norman GL, Papp M and Dalekos GN had the original idea for the study and wrote the study protocol; Gatselis NK, Tornai T, Zachou K, Saitis A, Gabeta S, Papp M and Dalekos GN diagnose, treat and follow the patients; Gatselis NK, Tornai T, Shums Z, Zachou K, Saitis A, Gabeta S and Albesa R made the laboratory determinations and collected the whole data from patients’ files as well as the analysis of the data; Gatselis NK, Norman GL and Dalekos GN made the statistical analysis and interpretation of the data and wrote the first draft of the manuscript; Dalekos GN and Gatselis NK wrote the final version of the paper after critical revision of the first draft; The rest authors also contributed to the final version of the manuscript; all authors have seen and approved the final draft of the paper.
Institutional review board statement: This study was reviewed and approved by the Ethics Committee of the two University Hospitals (General University Hospital of Larissa, Greece and University Hospital of Debrecen, Hungary).
Conflict-of-interest statement: This research did not receive any specific grant from funding agencies in the public, commercial, or not -for-profit sectors. However, Inova Diagnostics Inc. provided funds to Norman GL, Shums Z and Albesa R who are employees of Inova (ELISA kits), for the support of this study. All other authors have no disclosures relevant to this manuscript. Other authors have declared that no competing interest exists.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: George N Dalekos, MD, PhD, Full Professor, Head, Department of Medicine and Research Laboratory of Internal Medicine, National Expertise Center of Greece in Autoimmune Liver Diseases, General University Hospital of Larissa, Mezourlo, Larissa 41110, Greece. georgedalekos@gmail.com
Received: April 24, 2020
Peer-review started: April 24, 2020
First decision: May 15, 2020
Revised: May 19, 2020
Accepted: August 20, 2020
Article in press: August 20, 2020
Published online: September 14, 2020
Processing time: 138 Days and 4 Hours
Core Tip

Core Tip: This retrospective study evaluated the utility of serum Golgi protein-73 (GP73) determination as a diagnostic marker of cirrhosis and/or hepatocellular carcinoma (HCC) or as a predictor of liver disease progression in a large cohort of 632 consecutive patients suffering from diverse liver diseases diagnosed and followed in two tertiary care hospitals in Greece and Hungary. We found that GP73 was quite efficient for detecting cirrhosis and superior to Aspartate aminotransferase (AST)/Platelets (PLT) ratio index (APRI) determination. In combination with APRI score, its diagnostic performance can be further improved. Most importantly, however, the simple GP73 measurement proved promising for predicting a worse outcome during follow-up in patients with both viral and non-viral chronic liver diseases.